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KEY POINTS
 Thyroid hormone suppression therapy is a strategy to lower serum thyroid-stimulating
hormone (TSH) levels in patients with differentiated thyroid cancer in the hope that it
will improve outcomes.
 Evidence for improved outcomes with TSH suppression is lacking, except in patients with
the most advanced disease.
 Iatrogenic hyperthyroidism produced by thyroid hormone suppression therapy can lead to
adverse outcomes such as osteoporosis, fractures, and cardiovascular disease, including
atrial fibrillation.
 The use of thyroid hormone suppression should be based on initial risk of disease and
ongoing risk assessment of disease status. The lowest amount of thyroid hormone should
be used whenever possible.INTRODUCTION
The rationale behind thyroid hormone suppression therapy is the knowledge that
thyroid-stimulating hormone (TSH), secreted by the pituitary, affects growth and pro-
liferation of thyroid cancer cells.1 Several epidemiologic studies suggest that higher
serum TSH levels, even within the normal range, are associated with an increase in
the frequency of differentiated thyroid cancer (DTC) in patients with thyroid nodules,
as well as a more aggressive course in those patients with a thyroid cancer diag-
nosis.2–5 This theory is supported by a mutant mouse model in which there is altered
thyroid hormone receptor signaling, resulting in chronically elevated serum TSH levels,
with such mice developing a high frequency of metastatic thyroid cancer.6 In another
mouse model, in which thyroid cancer was induced by knock-in of the oncogenicThe authors have nothing to disclose.
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Biondi & Cooper228V600E BRAF mutation, the development of thyroid cancer was slowed considerably in
mice whose genome had the TSH receptor gene knocked out.7 Because of absence of
TSH receptor expression, these animals also have very high serum TSH levels.
Although thyroid cancer occurred, it was less aggressive than in animals that
expressed the wild-type TSH receptor. This suggests that, although TSH may not
be necessary for the initiation of thyroid cancer, TSH signaling is important for its main-
tenance and progression. On the other hand, suppression of TSH levels in animals
with the V600E mutation did not prevent the spread of thyroid cancer after it had
been established, possibly due to subsequent tumor-related alterations in TSH recep-
tor expression.8 This observation may support the idea that TSH suppression may be
of limited value in patients with more advanced thyroid cancer (see later discussion).CLINICAL STUDIES
All patients undergoing total thyroidectomy, as well as the very few patients who un-
dergo lobectomy, require thyroid hormone therapy to maintain normal serum TSH
levels. In contrast, the concept behind TSH suppressive therapy is that, at least theo-
retically, a subnormal serum TSH may lead to slower growth and spread of existing
DTC. In support of this idea, a 2002 meta-analysis of 10 studies published from the
1970s to the 1990s concluded that thyroid hormone suppression therapy was effica-
cious in decreasing thyroid cancer morbidity andmortality (relative risk 0.71, P<.05) for
adverse events (combined disease progression/recurrence and death).9 However,
these older studies did not necessarily distinguish replacement from suppression ther-
apy, and lacked modern technology (eg, ultrasound and thyroglobulin measurement)
to adequately detect small-volume recurrences. However, 2 subsequent studies pub-
lished more recently10,11 also concluded that aggressive serum TSH suppression led
to a survival benefit in patients with distant metastases, although the difference in
cause-specific survival did not reach statistical significance in 1 of the studies.10
Importantly, in the other study,11 no further survival benefit was noted in patients
with metastatic disease with serum TSH levels that were fully suppressed (<0.03
mU/L) compared with patients with serum TSH levels that were only suppressed to
less than 0.1 mU/L.
Studies from the National Thyroid Cancer Treatment Cooperative Study Group, a
thyroid cancer registry consortium in the United States, have concluded that the
most aggressive TSH suppression therapy was of no value in patients at low risk for
recurrence but was of benefit in high-risk patients.12,13 In the most recent analysis
from this prospective cohort involving almost 5000 subjects followed for a median
of 6 years, moderate degrees of TSH suppression, meaning serum TSH levels that
were consistently maintained in the subnormal (0.1–0.4 mU/L) to normal ranges
(0.4–4 mU/L) led to better outcomes in patients at all stages of disease, compared
with subjects whose serum TSH levels were in the normal to elevated ranges.14 How-
ever, benefits of TSH suppression were no longer observed after 5 years of follow-up.
This is consistent with an earlier Dutch study showing very low recurrence and mortal-
ity rates in subjects whose serum TSH levels were maintained at a median of less than
2 mU/l over a 9 year follow-up compared with subjects whose median serum TSH
levels were greater than 2 mU/L.15 In the only randomized prospective study of TSH
suppression in thyroid cancer, 400 Japanese subjects were randomized to receive
levothyroxine (L-T4) therapy to maintain serum TSH levels within the reference range
versus serum TSH levels less than 0.01 mU/L.16 After a mean follow-up of almost
7 years, there were no differences in disease-free survival between the 2 groups,
even when high-risk subjects were analyzed separately.16
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roidectomy or lobectomy for low-risk patients with DTC.17 Many patients undergoing
lobectomy will not require thyroid hormone replacement therapy to maintain serum
TSH levels within the reference range. A recent retrospective analysis by Park and col-
leagues18 of subjects with thyroid cancer who had undergone lobectomy showed that
the use of thyroid hormone to maintain serum TSH levels less than or equal to 2.0 mU/
L was of no benefit in terms of recurrence-free survival. Furthermore, even in those
subjects who did not receive L-T4 therapy, there was no difference in recurrence-
free survival in those subjects whose TSH levels were less than 2 mU/L compared
with subjects whose serum TSH levels were between 2 and 4.5 mU/L. However, there
were differences in dynamic risk stratification, with more subjects not receiving thyroid
hormone having biochemically indeterminate responses compared with those lobec-
tomized subjects who were receiving thyroid hormone treatment to maintain their TSH
levels at less than 2 mU/L (17.2% vs 9.4%).18 The study should be interpreted with
caution, however, because all subjects who underwent lobectomy also underwent
prophylactic ipsilateral central neck dissections, a procedure not generally performed
in the United States.
In general, daily L-T4 doses of 1.6 to 1.8 mg/kg are required to achieve a normal TSH
level in athyreotic individuals, whereas doses of 2.0 to 2.2 mg/kg are needed to sup-
press the serum TSH. However, the dose requirements in individual patients are highly
variable and depend on multiple factors, including body mass index, the use of
concomitant medications, and drug bioavailability, among others.
ADVERSE EFFECTS OF THYROID-STIMULATING HORMONE-SUPPRESSIVE THERAPY
WITH LEVOTHYROXINE
For many years, all patients with DTC likely received excessive L-T4 doses after thy-
roid surgery and radioiodine (RAI) ablation to intentionally suppress serum TSH at un-
detectable levels (TSH levels <0.01 mU/L with a third-generation sensitive assay).19,20
In these patients, serum free thyroxine (FT4) concentrations were often at the upper
limit of the reference range or frankly elevated.21–23 This condition, termed exogenous
(Exo) subclinical hyperthyroidism (SHyper), may be associated with symptoms and
signs of hyperthyroidism; impaired psychological, social, and physical quality of
life20,24–28; and adverse effects on the heart and skeleton, including increased cardio-
vascular (CV) morbidity and mortality, and increased risk of osteoporosis and
fractures.19
CARDIOVASCULAR MORBIDITY AND MORTALITY
Several retrospective studies reported that long-term TSH-suppressive therapy in-
creases heart rate and left ventricular mass (LVM)20,29–31; leads to myocardial strain30
and impaired diastolic function32–34; and reduces arterial elasticity,35 cardiac reserve,
and exercise capacity.36,37 Although none of these studies stratified the assessment of
CV morphology and function according to the level of TSH suppression, the increase
in LVM was related to the duration of TSH suppression more than to the thyroid hor-
mone levels in the circulation. These results suggest that the chronic hemodynamic
overload and persistent hyperkinetic CV state due to the slight thyroid hormone
excess was the main determinant of this concentric cardiac remodeling.19,38 The
negative alterations in CV morphology and function were reversible after beta-
blockade30,39 or the restoration of euthyroidism.38 Atrial fibrillation (AF) and a pro-
thrombotic state were the most important adverse events in DTC patients with Exo
SHyper and were responsible for the greater risk of hospitalization for CV disease
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sive therapy reported that the risk of CVD and dysrhythmias increased with age.41
Similarly, in 2 retrospective studies among 13642 and 51843 DTC subjects, a higher
prevalence of AF was found in the older group (18% vs 8% older than the age of
60 years vs younger than 60 years).42 The risk of AF was 17.5%, significantly higher
that the predicted sex-and age adjusted risks.42
In contrast, a prospective study reported that the risk of AF was comparable in 756
subjects with low risk and intermediate risk when serum TSH levels were less than or
equal to 0.4 mU/L or greater than 0.4 mU/L.44 Similarly, no correlation was found be-
tween the level of TSH and the occurrence of AF in 2 other studies.43,44 Interestingly,
the risk of AF was independent from the traditional risk factors,43 whereas it was corre-
lated with the cumulative dose of RAI.43 These data suggest a potential role of RAI on
cardiac inflammation, oxidative stress, or fibrosis because the sodium-iodine sym-
porter gene is expressed in cardiac tissue.45 All of these data could suggest that
advanced age, duration of TSH suppression, and coexistence of associated morbid-
ities are probably the main factors correlated with the negative CV prognosis of pa-
tients with Exo SHyper.
There are conflicting data on CV and all-cause mortality in DTC patients.40,46–49 In 1
large retrospective study, the risk of CV mortality increased 3.3-fold and the risk of all-
cause mortality increased 4.4-fold in subjects with DTC compared with controls.46
These risks were independent of age, sex, and CV risk factors. For each fold decrease
in geometric mean, TSH was independently linked with a 3.1-fold increased risk of CV
mortality.46 Regarding RAI therapy, no correlation with the cumulative RAI dose was
observed for the risk of all-cause mortality in patients treated with RAI ablation (cumu-
lative RAI dose 100 MCi), despite an increased risk of CVD morbidity compared with
the control group and to untreated patients.40 Therefore, the potential role of a
different degree of TSH suppression and the effects of RAI therapy on CV morbidity
and mortality remain to be established.RISK OF OSTEOPOROSIS
Thyroid hormone excess exerts important effects on bone remodeling by shortening
bone remodeling cycle and accelerating bone turnover.50 On the other hand, TSH is
a negative regulator of bone turnover and has a specific inhibitory effect on bone
resorption.51,52 Cross-sectional and longitudinal studies report conflicting findings
on the effects of Exo SHyper on bone turnover. Two overviews assessing the effects
of TSH suppressive therapy on bone mineral density (BMD) in patients with DTC sug-
gested that TSH suppression did not affect BMD in men or in premenopausal women,
whereas postmenopausal women were at risk of bone loss.53,54
Similarly, 2 meta-analyses55,56 on postmenopausal women with Exo SHyper found
a decrease in BMD with an annual bone mass loss of 0.91%.55 Some studies reported
that TSH suppressive therapy can affect trabecular bone microstructure as detected
by trabecular bone score measurement,57 peripheral high-resolution quantitative
computed tomography,58,59 or radiological vertebral fractures,60 which were found
in about one-third of women with DTC and was linked with the duration of treatment,
degree of TSH suppression, and age of patient.60
A prospective study in DTC subjects with low or intermediate risk suggested that
subjects with TSH suppression less than 0.4 mU/L had a higher incidence of osteopo-
rosis compared with nonsuppressed subjects (hazard ratio 2.1, P5 .05), and that pro-
longed TSH suppression with L-T4 increased the risk of postoperative osteoporosis in
DTC subjects.44 The duration of TSH suppression is an important factor to be
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receive TSH suppressive or no therapy reported that subjects with TSH suppressive
therapy had a significant deterioration in BMD from 1 year after surgery. Moreover,
a significant decrease in BMD was observed in older subjects (>50 years) but not in
younger subjects (<50 years). A marked deterioration in BMDwas reported in subjects
who continued TSH suppression for 5 years, especially in those with older age and
lower preoperative BMD.61 Subjects who did not receive TSH suppression did not
show any significant decrease in T-score until 5 years postoperatively.61 All of these
results suggest that a long-term TSH suppressive therapy is associated with bone
loss, especially in elderly patients and postmenopausal women.
FRACTURE RISK
Postmenopausal women with serum TSH levels lower than 0.1 mU/L during L-T4
treatment had a 2-fold to 4-fold greater risk of osteoporotic fracture compared with
the general population. The risk of fracture was associated with a strong dose-
response relation among adults aged 70 years or more.62 Several studies and
meta-analyses, including prospective studies, have confirmed the association be-
tween subclinical thyroid hormone excess and the risk of fractures, mainly in postmen-
opausal women.41,62–68 Most of these studies confirmed the associated between
duration of TSH suppression and increased fracture risk. The negative effects of the
slight thyroid hormone excess in SHyper on muscle strength, weight, and lean body
mass loss, as well as the possible association with a cognitive decline in elderly pa-
tients, could contribute to the increased risk of fractures in patients during TSH sup-
pressive therapy.69
EFFECTS OF HIGHER FREE THYROXINE LEVELS AND CARDIOVASCULAR RISK
Total T3 or FT3 levels are usually in the middle or lower part of the reference range in
Exo SHyper, with a consequent increased T4/T3 ratio.13–16 Therefore, endogenous
and Exo SHyper (caused by Graves’ disease or toxic nodular goiter) are not compa-
rable biochemically due to differences in severity and in the pattern of circulating thy-
roid hormone levels.69 This could suggest that a different mechanism of action may
explain the adverse effects of endogenous and Exo SHyper on the CV system and
bone structure. Some studies reported that high serum FT4 levels within the reference
range might be associated with negative health outcomes in elderly patients in terms
of AF and CV mortality.70–73 Elderly subjects with serum FT4 in the highest quartile of
their reference range can have an increased risk of AF and CV morbidity and mortal-
ity.70–73 Moreover, lower TSH and higher FT4 within the reference range were associ-
ated with 22% to 25% increased risk of hip fractures in euthyroid postmenopausal
women.74 Prospective studies are needed to assess the role of increased T4/T3 ratio
on the CV and bone risk in patients with DTC.
TREATMENT OF EXOGENOUS SUBCLINICAL HYPERTHYROIDISM
Large randomized controlled studies are required to prove causality in the cardiac and
skeletal effects, and to assess the efficacy of TSH normalization on CV risk and frac-
tures. No study has evaluated the effects of beta-blocking drugs on CVmortality, even
though these drugs can improve CV parameters associated with increased morbidity
in the general population. Treatment with alendronate could prevent trabecular bone
loss in patients with thyroid cancer receiving thyroxine replacement.75 However, the
potential risk of AF should be considered and a risk-benefit assessment made.76
Fig. 1. 2015 ATA Thyroid Guidelines: long-term TSH suppression. a TSH target for patients
with a biochemical incomplete response can be quite different based on original ATA risk,
thyroglobulin (Tg) level, Tg trend over time, and risk of TSH suppression.
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Given the evidence that aggressive TSH suppression is of little to no benefit to almost
all patients with thyroid cancer who are at low risk of recurrence and death, the ATA
recommends a graded algorithm, considering that the potential benefits of such ther-
apy must be balanced against CV and skeletal risks (Fig. 1).17 Using the concept of
ongoing risk stratification, the ATA recommends maintaining serum TSH levels be-
tween 0.5 and 2 mU/L in low-risk and intermediate-risk patients with an excellent
response to treatment but using mild TSH suppression (TSH 0.1–0.5 mU/L) in high-
risk patients who have had an excellent response (negative imaging and undetectable
suppressed thyroglobulin). Mild TSH suppression is also recommended in patients
with a biochemically incomplete response. More significant TSH suppression (ie,
serum TSH <0.1 but not necessarily undetectable) is recommended in patients with
residual structural disease or a biochemically incomplete response if they are young
or at low risk of complications from Exo SHyper. Ongoing assessment of the patient’s
clinical disease status, as well as the temporal development of risk factors such as
advanced age, postmenopausal state, and the development of osteoporosis and/or
CVD are essential to prevent the treatment from becoming worse for the patient
than the disease being treated.
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